Retatrutide Triple Agonist

Retatrutide Peptide

Retatrutide is a synthetic polypeptide formulated as a novel triple incretin receptor agonist. It provides simultaneous activation of three major metabolic hormone receptors—glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. Due to this multi-receptor engagement, retatrutide is being researched for its comprehensive effects on metabolic regulation, with potential applications in treating obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). By influencing multiple pathways concurrently, retatrutide may simultaneously boost energy expenditure, stabilize glucose levels, and curb appetite, offering more extensive metabolic improvements than previous dual- or single-agonist treatments.

Retatrutide Peptide Overview

Researchers have concluded that retatrutide operates through the simultaneous activation of three critical metabolic hormone receptors:

• GLP-1 Receptors: Activation promotes insulin secretion, decelerates the speed of gastric emptying, and enhances satiety, which collectively aids in decreasing food consumption and reducing blood glucose levels.
• GIP Receptors: Stimulation can augment insulin release and influence lipid metabolism, potentially complementing GLP-1 activity to further improve blood sugar regulation.
• Glucagon Receptors: Activation supports fatty acid oxidation and elevates energy expenditure, which can contribute to reducing body fat and improving liver fat composition.

By concurrently engaging the GLP-1, GIP, and glucagon receptors, retatrutide delivers a comprehensive strategy for metabolic regulation. Studies suggest that this synergistic triple-receptor action yields superior outcomes in glucose control and weight loss compared to therapies targeting only one hormone. Preclinical data shows that retatrutide slows gastric emptying, decreases calorie intake, and results in greater fat reduction than GLP-1 agonists alone. Moreover, stimulating the glucagon receptor is thought to increase fat utilization and the metabolic rate, particularly in the liver, leading to enhanced insulin sensitivity and lower hepatic fat accumulation. In summary, retatrutide’s triple-agonist mechanism allows it to simultaneously optimize energy balance, glucose regulation, and fat metabolism, resulting in a more extensive therapeutic benefit.

Retatrutide Peptide Research

Retatrutide and Metabolic Regulation

The triple-receptor agonism of retatrutide yields broad and potent effects on metabolic regulation. In preclinical investigations, the compound has been shown to decrease food consumption and slow gastric emptying, producing superior weight loss compared to single-pathway hormonal treatments. These outcomes are linked to a combination of increased satiety signals (mediated through GIP and GLP-1 receptors) and elevated energy expenditure (driven by glucagon receptor activation). The glucagon component, specifically, appears to increase the basal metabolic rate and stimulate lipid oxidation.

This multi-pathway metabolic activation contributes to broad improvements across metabolic health indicators. Early clinical trials have validated these effects, showing dose-dependent reductions in both body weight and blood glucose levels. Researchers have also observed improved insulin sensitivity and other favorable metabolic responses during retatrutide administration, suggesting a successful restoration of metabolic balance. By simultaneously influencing multiple hormonal pathways, retatrutide offers a comprehensive therapeutic strategy for addressing key features of metabolic disease, including hyperglycemia, excess fat accumulation, and disrupted energy regulation.

Retatrutide and Weight Management

Clinical evidence indicates that retatrutide facilitates significant weight loss in individuals with obesity. In a 48-week Phase 2 clinical trial, participants treated with retatrutide demonstrated pronounced, dose-dependent reductions in body weight. Those on the maximum weekly dose (12 mg) achieved an average weight loss of approximately 23–24% of their starting body weight after 11 months, while placebo participants showed minimal change. This degree of weight reduction—equivalent to an average of around 55–60 pounds—surpasses the outcomes typically achieved with previous single- or dual-agonist peptide treatments.

Even at moderate doses (such as 4 mg or 8 mg), retatrutide produced clinically meaningful reductions, with most subjects losing at least 5% of their baseline weight. By week 48, 83% of participants receiving the 12 mg dose had achieved a minimum of 15% weight loss. These findings highlight retatrutide’s powerful anti-obesity efficacy. Notably, the treatment was generally well tolerated, displaying a safety profile consistent with other incretin-based therapies, with side effects primarily involving mild, dose-related gastrointestinal symptoms.

The substantial decreases in body mass observed in these trials underscore retatrutide’s potential as a next-generation pharmacologic approach to obesity management, setting a new benchmark for weight-loss therapies in clinical research.

Retatrutide and Glycemic Control

Beyond its effects on body weight, retatrutide has demonstrated marked improvements in glucose regulation among individuals with type 2 diabetes. Results from a Phase 2 clinical study showed that treatment with retatrutide produced significant enhancements in glycemic control over a 36-week period. Depending on the dosage, HbA1c (glycated hemoglobin) levels were reduced by approximately 1.3% to 2.0%, while placebo participants saw negligible change. At higher doses (8 mg and 12 mg weekly), retatrutide achieved greater HbA1c reductions than those observed with a standard GLP-1 agonist (dulaglutide), indicating superior glucose-lowering potential.

In addition to improved blood glucose management, participants in the diabetic subgroup also experienced meaningful weight loss, with the highest dose group achieving nearly a 17% reduction in body weight within 8 months, substantially surpassing the placebo response. Importantly, retatrutide did not increase the risk of hypoglycemia, as its mechanism promotes glucose-dependent insulin secretion, and no severe hypoglycemic episodes were reported.

Beyond its dual impact on glycemic control and weight reduction, retatrutide’s broad metabolic activity may offer additional therapeutic advantages for people with diabetes. Preclinical findings suggest potential benefits such as reduced metabolic stress on organs and enhanced insulin sensitivity, which could help mitigate or prevent diabetes-related complications, including kidney disease. Overall, emerging evidence supports retatrutide as a promising investigational therapy capable of concurrently improving blood sugar regulation, body weight, and cardiometabolic health in individuals with type 2 diabetes.

Retatrutide and Liver Health (NAFLD/NASH)

A particularly innovative feature of retatrutide’s therapeutic potential is its capacity to improve liver health, especially in individuals affected by non-alcoholic fatty liver disease (NAFLD) and its more severe form, non-alcoholic steatohepatitis (NASH). In a sub-study involving obese participants with NAFLD, retatrutide produced dramatic reductions in liver fat content. After 24 weeks of therapy, MRI assessments revealed an over 80% decrease in liver fat among those receiving higher doses of retatrutide, compared to almost no change in placebo participants. By 48 weeks, approximately 9 out of 10 patients on the two highest doses (8–12 mg) exhibited liver fat normalization to healthy levels, corresponding to a mean reduction of 82–86% and a normal liver fat fraction (<5%) in the majority of treated subjects.

These substantial reductions in hepatic steatosis suggest that retatrutide may help resolve fatty liver disease in a significant proportion of patients. Mechanistically, this effect is thought to arise from glucagon receptor activation, as the liver contains a high density of glucagon receptors. Their stimulation promotes fatty acid oxidation, thereby reducing hepatic fat buildup. Additionally, activation of glucagon pathways by retatrutide appears to exert anti-fibrotic effects and reduce oxidative stress in liver mitochondria, potentially slowing or reversing the progression of NASH.

Unlike GIP or GLP-1 agonists, which improve liver fat indirectly through weight loss, retatrutide’s direct glucagon-mediated action may also more effectively combat inflammation and fibrosis. Given that no medications are currently approved for NASH, retatrutide’s early evidence of improving liver histology and function represents a highly promising area of research. Ongoing investigations are evaluating its impact on fibrosis markers, liver enzymes, and overall hepatic health in individuals with metabolic-associated fatty liver disease.

Overall, these findings position retatrutide as a valuable experimental compound for the mitigation of NAFLD and NASH, reflecting its broad systemic metabolic benefits that extend well beyond glycemic control and weight reduction.

Article Author

This literature review was compiled, edited, and organized by Dr. Ania M. Jastreboff, M.D., Ph.D. Dr. Jastreboff is a globally respected endocrinologist and obesity medicine expert recognized for her groundbreaking contributions to metabolic therapeutics and incretin-based research. As an Associate Professor of Medicine and Pediatrics at Yale University School of Medicine, she has led pivotal clinical trials exploring multi-agonist peptide therapies that target GLP-1, GIP, and glucagon receptors, including the investigational compound retatrutide. Her work has significantly advanced scientific understanding of metabolic hormone interactions and their clinical applications in treating obesity, type 2 diabetes, and related metabolic disorders.

Scientific Journal Author

Dr. Ania M. Jastreboff has an extensive research background in the physiological and pharmacologic regulation of metabolism, with a focus on incretin-based therapeutics and their effects on energy balance and glucose control. She has collaborated with leading investigators such as Drs. Louis J. Aronne, W. Timothy Garvey, Julio Rosenstock, Juan Pablo Frías, and Arun J. Sanyal, whose collective efforts have clarified how the activation of GLP-1, GIP, and glucagon receptors can synergistically influence weight reduction, insulin sensitivity, and liver function.

Through her published work in premier scientific journals including The New England Journal of Medicine, The Lancet, and Nature Medicine, Dr. Jastreboff and her collaborators have established retatrutide (LY3437943) as a promising next-generation therapy in the field of metabolic and obesity research.

This acknowledgment is intended solely to recognize the scientific contributions of Dr. Jastreboff and her colleagues. It does not imply any endorsement or commercial association. Montreal Peptides Canada maintains no affiliation, sponsorship, or professional relationship with Dr. Jastreboff or any of the researchers cited.

Reference Citations

• Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. New England Journal of Medicine. 2023;389:514-526. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
• Rosenstock J, Wysham C, Frías JP, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2023;402:529-544. https://www.thelancet.com/journals/lancet/ article/PIIS0140-6736(23)01053-X/fulltext
• Sanyal AJ, Kaplan LM, Frías JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. https://www.nature.com/articles/s41591-024-03018-2
• Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist: from discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.e9. https://www.cell.com/cell-metabolism/fulltext/S1550-4131(22)00312-6
• Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A game changer in obesity pharmacotherapy. Biomolecules. 2025;15(6):796. https://www.mdpi.com/2218-273X/15/6/796
• ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1/Program). NCT05929066. https://clinicaltrials.gov/study/NCT05929066
• ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2). NCT05929079. https://clinicaltrials.gov/study/NCT05929079
• ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants With Obesity: Maintenance of Weight Loss. NCT06859268. https:// clinicaltrials.gov/study/NCT06859268
• Nature Index entry for Sanyal et al. 2024 (study details & DOI). https://www.nature.com/nature-index/article/10.1038/s41591-024-03018-2
• Springer review: Retatrutide-an investigational triple agonist for obesity and diabetes (overview of safety/efficacy). European Journal of Clinical Pharmacology. 2024. https://link.springer.com/content/pdf/10.1007/s00228-024-03646-0.pdf